Chinese Agencies’ Agreement Could Halve Approval Time For U.S. Devices
This article was originally published in PharmAsia News
Executive Summary
Chinese approval time for imported medical devices could be cut in half under an agreement to reduce redundancies between the country's Administration of Quality Supervision, Inspection and Quarantine and its State FDA
You may also be interested in...
China Pledges To Accelerate Drug Reimbursement Process
China has agreed to update its national and regional drug reimbursement lists every two years, which should expand market access for new drugs developed by multinational companies
China Pledges To Accelerate Drug Reimbursement Process
China has agreed to update its national and regional drug reimbursement lists every two years, which should expand market access for new drugs developed by multinational companies
U.S.-China Device Talks Yield Some Concessions, But Big Issues Unresolved
A recent meeting between U.S. and Chinese government officials and device industry reps yielded some concessions to opening up China's market, but left many more issues on the table, according to a U.S. industry participant